💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Acoramidis Hydrochloride

CHEMBL4650226 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
328.8 g/mol
LogP
—
Phase
4

The hydrochloride salt formulation of acoramidis, a transthyretin stabilizer used to treat transthyretin amyloid cardiomyopathy. It works identically to acoramidis, binding to the transthyretin protein and preventing it from dissociating into the misfolded fragments that accumulate as amyloid in cardiac tissue. Consistent three-times-daily dosing is important to maintain adequate drug levels for effective protein stabilization.

الوزن الجزيئي

328,7600 g/mol

TPSA

75,20 Ų

آلية العمل

Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C15H17FN2O3.ClH/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16;/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20);1H

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H18ClFN2O3

                    

                    
                    

                        
HBD / HBA

                        
3 / 5

                    

                    
                    

                        
الروابط القابلة للدوران

                        
6

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
The hydrochloride salt formulation of acoramidis, a transthyretin stabilizer used to treat transthyretin amyloid cardiomyopathy. It works identically to acoramidis, binding to the transthyretin protein and preventing it from dissociating into the misfolded fragments that accumulate as amyloid in cardiac tissue. Consistent three-times-daily dosing is important to maintain adequate drug levels for effective protein stabilization.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Acoramidis Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4650226.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 135307127.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.